BionX™ Medical Technologies
1
10M
1
0.07
1
- Areas of investment
Summary
BionXu2122 Medical Technologies appeared to be the Corporate Investor, which was created in 2007. The fund was located in North America if to be more exact in United States. The main office of represented Corporate Investor is situated in the Bedford.
Among the most popular portfolio startups of the fund, we may highlight 4SC. Among the most successful fund investment fields, there are Biotechnology, Biopharma. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. For fund there is no match between the location of its establishment and the land of its numerous investments - Germany.
The common things for fund are deals in the range of 5 - 10 millions dollars. The important activity for fund was in 2003. The fund is constantly included in less than 2 deals per year. The increased amount of exits for fund were in 2011.
The typical case for the fund is to invest in rounds with 4 participants. Despite the BionXu2122 Medical Technologies, startups are often financed by Deutsche Venture Capital, BioM AG, Beteiligungsgesellschaft Neue Lu00e4nder. The meaningful sponsors for the fund in investment in the same round are Mulligan BioCapital, Deutsche Venture Capital, 3i Group. In the next rounds fund is usually obtained by Wellington Partners, Santo Holding.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Exits
- 1
- Rounds per year
- 0.07
- Investments by industry
- Therapeutics (1)
- Biotechnology (1)
- Biopharma (1)
- Investments by region
-
- Germany (1)
- Peak activity year
- 2003
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 24
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| 4SC | 21 May 2003 | Biotechnology, Therapeutics, Biopharma | Late Stage Venture | 10M | Germany, Bavaria, Germany |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.